CORT Earnings

CORT reported its earnings on 2026-02-24, showcasing a revenue of 202.13M against an estimate of 254.39M, resulting in a -20.55% surprise. The EPS was 0.2, surpassing the expected 0.27 by -25.93%. The stock experienced a -0.71% price change on the earnings day and a -1.4% change over the next five days, reflecting market reactions to the results.

Following CORT's earnings announcement on 2026-02-24, the stock price moved by -0.71% on the day of the release. Over the subsequent five days, it saw a -1.4% change. Historically, CORT's stock price tends to shift by an average of -0.45% in the 10 days leading up to earnings and 1.65% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate CORT's annual revenue to reach 200.83M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised downward by -1.69% and EPS estimates revised upward by 0.44% over the past three months, indicating analyst expectation in the company's performance.

The correlation between CORT's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were revised downward by -1.69%, while EPS estimates moved revised upward by 0.44%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, CORT's stock price typically moves by -0.45% in the 10 days before its earnings and 1.65% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 0.00 and revenue of 200.83M.

The company's earnings call highlights strong revenue growth, a successful stock repurchase program, and strategic pharmacy transitions to meet demand. Despite a decline in net income, the optimistic guidance and potential FDA approvals for relacorilant support a positive outlook. The Q&A section reveals confidence in resolving supply chain issues and potential new oncology standards. However, uncertainties with the FDA and price erosion concerns slightly temper the sentiment. Given the market cap, the stock is likely to react positively, with a predicted movement of 2% to 8% over the next two weeks.